{
    "ticker": "AIMAU",
    "name": "AIM ImmunoTech Inc.",
    "description": "AIM ImmunoTech Inc. is a biotechnology company dedicated to the development of novel therapies for the treatment of cancer and viral infections. Founded in 1983 and headquartered in Ocala, Florida, AIM ImmunoTech focuses on the development of its lead product candidate, Ampligen (rintatolimod), an experimental immunotherapy with potential applications in various oncological and viral indications, including chronic fatigue syndrome. The company is committed to advancing its clinical programs through rigorous research and development, aiming to harness the body's immune system to fight diseases more effectively. AIM's innovative approach is built on a foundation of scientific discovery, and it collaborates with academic institutions and clinical research organizations to further its mission. In addition to Ampligen, AIM ImmunoTech is exploring other compounds that could enhance immune response and improve treatment outcomes for patients. The company actively engages with the medical community and aims to bring hope to patients suffering from debilitating conditions by providing novel therapeutic options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Ocala, Florida, USA",
    "founded": "1983",
    "website": "https://www.aimimmunotech.com",
    "ceo": "Thomas K. Equels",
    "social_media": {
        "twitter": "https://twitter.com/AIMImmunoTech",
        "linkedin": "https://www.linkedin.com/company/aim-immunotech/"
    },
    "investor_relations": "https://www.aimimmunotech.com/investors",
    "key_executives": [
        {
            "name": "Thomas K. Equels",
            "position": "CEO"
        },
        {
            "name": "Dr. Charles L. Theuer",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Ampligen"
            ]
        }
    ],
    "seo": {
        "meta_title": "AIM ImmunoTech Inc. | Biotechnology and Immunotherapy",
        "meta_description": "Explore AIM ImmunoTech Inc., a biotechnology company focused on innovative therapies for cancer and viral infections. Discover their lead product, Ampligen, and their commitment to advancing healthcare.",
        "keywords": [
            "AIM ImmunoTech",
            "Biotechnology",
            "Cancer Treatment",
            "Immunotherapy",
            "Ampligen"
        ]
    },
    "faq": [
        {
            "question": "What is AIM ImmunoTech known for?",
            "answer": "AIM ImmunoTech is known for its development of the experimental immunotherapy Ampligen and its focus on cancer and viral infections."
        },
        {
            "question": "Who is the CEO of AIM ImmunoTech?",
            "answer": "Thomas K. Equels is the CEO of AIM ImmunoTech Inc."
        },
        {
            "question": "Where is AIM ImmunoTech headquartered?",
            "answer": "AIM ImmunoTech is headquartered in Ocala, Florida, USA."
        },
        {
            "question": "What is Ampligen?",
            "answer": "Ampligen is an experimental immunotherapy being developed by AIM ImmunoTech for various oncological and viral indications."
        },
        {
            "question": "When was AIM ImmunoTech founded?",
            "answer": "AIM ImmunoTech was founded in 1983."
        }
    ],
    "competitors": [
        "IMMP",
        "CARA",
        "KPTI",
        "ZIOP"
    ],
    "related_stocks": [
        "XLRN",
        "SRPT",
        "CRIS",
        "RGEN"
    ]
}